Tolero Pharmaceuticals Presents Positive Clinical and Preclinical Data on Programs in Leukemia and Anemia at the 57th ASH Annual Meeting and Exposition

SALT LAKE CITY--()--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present one oral and three poster presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 5 through 8, 2015. The presentations include nonclinical results that further support the development of Tolero’s clinical and preclinical pipeline of agents, including the CDK9 inhibitor (alvocidib), the Axl kinase inhibitor (TP-0903), and the ALK2 inhibitor (TP-0184).

Details of the oral presentation is as follows:

Publication Number: #273
Title: ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease
Presenter: Steven L. Warner, PhD
Session Title: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Heme and Anemia
Session Date & Time: Sunday, December 6, 2015, 4:30 PM-6:00 PM ET
Presentation Time: 5:00 PM ET
Location: Orange County Convention Center, W414AB, Level 4

Details of the poster presentations are as follows:

Abstract: #1343
Title: Alvocidib Potentiates the Activity of Azacytidine in an MCL-1 Dependent Fashion
Presenter: Wontak KimSession Title: 615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation: Poster I
Date: Saturday, December 5, 2015
Presentation Time: 5:30 PM-7:30 PM ET
Location: Orange County Convention Center, Hall A, Level 2

Abstract: #3253
Title: Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling
Presenter: Katherine K. Soh
Session Title: 802. Chemical Biology and Experimental Therapeutics: Poster II
Date: Sunday, December 6, 2015
Presentation Time: 6:00 PM-8:00 PM ET
Location: Orange County Convention Center, Hall A, Level 2

Abstract: #3799
Title: Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML
Presenter: Wontak Kim
Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Date: Monday, December 7, 2015
Presentation Time: 6:00 PM-8:00 PM ET
Location: Orange County Convention Center, Hall A, Level 2

About Tolero
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.

Contacts

Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003
bizdev@toleropharma.com